Klinik und Poliklinik für Gastroenterologie und Rheumatologie
 Universitätsmedizin Leipzig

Publikationen

2016

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection.
Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V, Fischer J, Berg T, Aghemo A, Cheroni C, Francesco R de, Fargion S, Colombo M, Datz C, Stickel F, Valenti L, Romeo S.
Hepatology (2016) 63:418–427. doi:10.1002/hep.28322.

Flares during long-term entecavir therapy in chronic hepatitis B.
Chi H, Arends P, Reijnders JGP, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, Knegt RJ de, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HLA.
J Gastroenterol Hepatol. (2016) doi:10.1111/jgh.13377.

Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival.
Engelmann C, Krohn S, Prywerek D, Hartmann J, Herber A, Boehlig A, Zeller K, Boehm S, Berg T.
Eur J Gastroenterol Hepatol (2016) 28:1285–1292. doi:10.1097/MEG.0000000000000712.

Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure.
Engelmann C, Splith K, Berg T, Schmelzle M.
Eur J Intern Med. (2016) doi:10.1016/j.ejim.2016.09.006.

FibroGENE: A gene-based model for staging liver fibrosis.<br />Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HLY, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Nattermann J, Riordan S, Miele L, Kelaeng KS, Ampuero J, Ahlenstiel G, McLeod D, Powell E, Liddle C, Douglas MW, Booth DR, George J.
J Hepatol (2016) 64:390–398. doi:10.1016/j.jhep.2015.11.008.

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M, Mangia A, Berg T, Chan HLY, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MAM, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J. 
Hepatology (2016) 64:34–46. doi:10.1002/hep.28475.

Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Fischer J, Weber ANR, Bohm S, Dickhofer S, El Maadidi S, Deichsel D, Knop V, Klinker H, Moller B, Rasenack J, Wang L, Sharma M, Hinrichsen H, Spengler U, Buggisch P, Sarrazin C, Pawlita M, Waterboer T, Wiese M, Probst-Muller E, Malinverni R, Bochud P, Gardiner CM, O'Farrelly C, Berg T.
Gut (2016) doi:10.1136/gutjnl-2015-310239.

Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
Fulop B, Mihm U, Rohde P, Buggisch P, Schlosser B, Biermer M, Brodzinski A, Fischer J, Bohm S, van Bommel F, Sarrazin C, Berg T.
J Viral Hepat (2016) 23:866–872. doi:10.1111/jvh.12562.

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation. Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).
Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P.
The Lancet Infectious Diseases (2016) 16:606–617. doi:10.1016/S1473-3099(16)00118-3.

Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection.
Mueller T, Fischer J, Gessner R, Rosendahl J, Bohm S, van Bommel F, Knop V, Sarrazin C, Witt H, Marques AM, Kovacs P, Schleinitz D, Stumvoll M, Bluher M, Bugert P, Schott E, Berg T.
Liver Int (2016) 36:1267–1274. doi:10.1111/liv.13094.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.
Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Gronbaek H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M.
Nat Commun (2016) 7:12757. doi:10.1038/ncomms12757.

Clinical Trial Watch: Reports from the Liver Meeting(R), AASLD, San Francisco, November 2015.
Wiegand J, van Bommel F, Duarte-Rojo A, Altamirano J, Abraldes JG, Villanueva A, Berg T. 2016. 
J Hepatol 64:1428–1445. doi:10.1016/j.jhep.2016.02.020.

Bistable epigenetic states explain age-dependent decline in mesenchymal stem cell heterogeneity.
Hamidouche Z, Rother K, Przybilla J, Krinner A, Clay D, Hopp L, Fabian C, Stolzing A, Binder H, Charbord P, Galle J. 2016. 
Stem Cells. doi:10.1002/stem.2514.

Stem cell competition in the gut: insights from multi-scale computational modelling.
Thalheim T, Buske P, Przybilla J, Rother K, Loeffler M, Galle J. 2016. 
J R Soc Interface 13. doi:10.1098/rsif.2016.0218.

 

2015

Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JGP, Oo Y, Petersen J, van Bommel F, Knegt RJ de, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HLA. 2015.
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Gut 64:1289–1295. doi:10.1136/gutjnl-2014-307023.

Holzmann C, Kappel S, Kilch T, Jochum MM, Urban SK, Jung V, Stockle M, Rother K, Greiner M, Peinelt C. 2015.
Transient receptor potential melastatin 4 channel contributes to migration of androgen-insensitive prostate cancer cells.
Oncotarget 6:41783–41793. doi:10.18632/oncotarget.6157.

Casper M, Mengel M, Fuhrmann C, Herrmann E, Appenrodt B, Schiedermaier P, Reichert M, Bruns T, Engelmann C, Grunhage F, Lammert F. 2015.
The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial. Trials 16:83. doi:10.1186/s13063-015-0594-4.

Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HLK, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G. 2015.
Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.
Nat Commun 6:6422. doi:10.1038/ncomms7422.

Karlas T, Kollmeier J, Bohm S, Muller J, Kovacs P, Troltzsch M, Weimann A, Bartels M, Rosendahl J, Mossner J, Berg T, Keim V, Wiegand J. 2015.
Noninvasive characterization of graft steatosis after liver transplantation. Scand J Gastroenterol 50:224–232. doi:10.3109/00365521.2014.983156.

Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, Nicola S de, Fracanzani AL, D'Ambrosio R, Maggioni M, Francesco R de, Fargion S, Berg T, Stickel F, Hampe J, Romeo S, Colombo M, Valenti L. 2015.
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology 62:111–117. doi:10.1002/hep.27811.

van Bommel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, Edelmann A. 2015. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61:66–76. doi:10.1002/hep.27381.

Wang H, El Maadidi S, Fischer J, Grabski E, Dickhofer S, Klimosch S, Flannery SM, Filomena A, Wolz O, Schneiderhan-Marra N, Loffler MW, Wiese M, Pichulik T, Mullhaupt B, Semela D, Dufour J, Bochud P, Bowie AG, Kalinke U, Berg T, Weber ANR. 2015.
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.
Hepatology 62:1375–1387. doi:10.1002/hep.28105.

Wils E, van den Berg T, van Bommel J. 2015.
Current practice of target temperature management post-cardiac arrest in The Netherlands, a post-TTM trial survey. Resuscitation 97:e1-2. doi:10.1016/j.resuscitation.2015.06.031.

 

2014

Boer YS de, van Gerven, Nicole M F, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JPH, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MMJ, Vrolijk JM, Kraal G, Mulder CJJ, van Nieuwkerk, Carin M J, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Volzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G. 2014. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147:443-52.e5. doi:10.1053/j.gastro.2014.04.022.

Karlas T, Petroff D, Garnov N, Bohm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A, Busse H, Kahn T, Mossner J, Berg T, Troltzsch M, Keim V, Wiegand J. 2014.
Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 9:e91987. doi:10.1371/journal.pone.0091987.

Krohn S, Bohm S, Engelmann C, Hartmann J, Brodzinski A, Chatzinotas A, Zeller K, Prywerek D, Fetzer I, Berg T. 2014.
Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites. J Clin Microbiol 52:1754–1757. doi:10.1128/JCM.00552-14.

Marino Z, van Bommel F, Forns X, Berg T. 2014.
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 63:207–215. doi:10.1136/gutjnl-2013-305771.

Mihm U, Welker M, Teuber G, Wedemeyer H, Berg T, Sarrazin C, Bohm S, Alshuth U, Herrmann E, Zeuzem S. 2014.
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J Viral Hepat 21:42–52. doi:10.1111/jvh.12124.

Nischalke HD, Lutz P, Kramer B, Sohne J, Muller T, Rosendahl J, Fischer J, Berg T, Hittatiya K, Fischer H, Soyka M, Semmo N, Nattermann J, Sauerbruch T, Strassburg CP, Stickel F, Spengler U. 2014.
A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. J Hepatol 61:1073–1079. doi:10.1016/j.jhep.2014.06.006.

Strnad P, Nuraldeen R, Fischer J, Berg T, Trautwein C. 2014.
Hepcidin as a predictor of treatment response in chronic hepatitis C infection. Hepatology 59:1648. doi:10.1002/hep.26656.

van Bommel F, Berg T. 2014.
Antiviral therapy of chronic hepatitis B. Intervirology 57:171–180. doi:10.1159/000360945.

Wiese M, Fischer J, Lobermann M, Gobel U, Grungreiff K, Guthoff W, Kullig U, Richter F, Schiefke I, Tenckhoff H, Zipprich A, Berg T, Muller T. 2014.
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 59:49–57. doi:10.1002/hep.26644.

 

2013

Engelmann C, Berg T. 2013.
Akutes und akut-auf-chronisches Leberversagen. Dtsch Med Wochenschr 138:1574–1577. doi:10.1055/s-0033-1343281.

Fischer J, Bohm S, George J, Sarrazin C, Berg T. 2013.
Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection. Hepatology 57:416–417. doi:10.1002/hep.25923.

Fischer J, Bohm S, Muller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fulop B, van Bommel F, George J, Berg T. 2013.
Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection.
PLoS One 8:e77530. doi:10.1371/journal.pone.0077530.

Kant J, Moller B, Heyne R, Herber A, Bohm S, Maier M, Liebert UG, Mossner J, Berg T, Wiegand J. 2013.
Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection.
Eur J Gastroenterol Hepatol 25:416–420. doi:10.1097/MEG.0b013e32835c502d.

Knop V, Bergk A, Schlosser B, Thieringer J, van Bommel F, Frost N, Kintscher U, Berg T. 2013. Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. Eur J Gastroenterol Hepatol 25:594–600. doi:10.1097/MEG.0b013e32835cc878.

Nischalke HD, Berger C, Lutz P, Langhans B, Wolter F, Eisenhardt M, Kramer B, Kokordelis P, Glassner A, Muller T, Rosendahl J, Fischer J, Berg T, Grunhage F, Leifeld L, Soyka M, Nattermann J, Sauerbruch T, Stickel F, Spengler U. 2013.
Influence of the CXCL1 rs4074 A allele on alcohol induced cirrhosis and HCC in patients of European descent. PLoS One 8:e80848. doi:10.1371/journal.pone.0080848.

van Bommel F, Berg T. 2013.
Treatment of HBV related cirrhosis. Liver Int 33 Suppl 1:176–181. doi:10.1111/liv.12074.

Lupp S, Gumhold C, Ampofo E, Montenarh M, Rother K. 2013.
CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2alpha and CK2beta gene expressions. Mol Cell Biochem 384:71–82. doi:10.1007/s11010-013-1782-8.

Fischer M, Grundke I, Sohr S, Quaas M, Hoffmann S, Knorck A, Gumhold C, Rother K. 2013.
p53 and cell cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHR promoter element bound by DREAM and MMB complexes.
PLoS One 8:e63187. doi:10.1371/journal.pone.0063187.

 

2012

Biermer M, Schlosser B, Fulop B, van Bommel F, Brodzinski A, Heyne R, Keller K, Sarrazin C, Berg T. 2012.
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
J Viral Hepat 19:547–553. doi:10.1111/j.1365-2893.2011.01572.x.

Bruns T, Reuken PA, Fischer J, Berg T, Stallmach A. 2012.
Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. J Hepatol 56:1207-8; author reply 1208-9. doi:10.1016/j.jhep.2011.09.010.

Fischer J, Bohm S, Scholz M, Muller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bommel F, Brodzinski A, Fulop B, Migaud P, Berg T. 2012. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 55:1700–1710. doi:10.1002/hep.25582.

Rosendahl J, Tonjes A, Schleinitz D, Kovacs P, Wiegand J, Ruffert C, Jesinghaus M, Schober R, Herms M, Grutzmann R, Schulz H, Stickel F, Werner J, Bugert P, Bluher M, Stumvoll M, Bohm S, Berg T, Wittenburg H, Mossner J, te Morsche R, Derikx M, Keim V, Witt H, Drenth JPH. 2012.
A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. PLoS One 7:e29433. doi:10.1371/journal.pone.0029433.

van Bommel F, Trojan J, Deterding K, Wedemeyer H, Wasmuth HE, Huppe D, Moller B, Bock FJ, Feucht H, Berg T. 2012.
Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther 17:1049–1058. doi:10.3851/IMP2307.

 

2011

Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns MP. 2011. Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z Gastroenterol 49:871–930. doi:10.1055/s-0031-1273462.

Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL, Berg T, Wedemeyer H, Tenckhoff H, Wiese M, Kullig U, Gobel U, Capka E, Schiefke I, Guthof W, Grungreiff K, Konig I, Roggendorf M, Sauerbruch T, Spengler U. 2011.
The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Delta32 mutation.
J Hepatol 55:1201–1206. doi:10.1016/j.jhep.2011.03.011.

Schlosser B, Biermer M, Weich V, van Bommel F, Berg T. 2011.
Long-term evaluation of patients with sustained virologic remission by highly sensitive HCV RNA assays: no evidence for viral persistence.
J Clin Virol 50:88–89. doi:10.1016/j.jcv.2010.09.004.

Wiegand J, Neumann K, Bohm S, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T. 2011.
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. Clin Infect Dis 53:1111–1114. doi:10.1093/cid/cir670.

Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bommel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HLA. 2011.
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response.
Hepatology 54:443–451. doi:10.1002/hep.24406.

Bohlig L, Rother K. 2011.
One function--multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol 2011:464916. doi:10.1155/2011/464916.

 

 
Letzte Änderung: 07.11.2016, 16:56 Uhr
Zurück zum Seitenanfang springen
Klinik und Poliklinik für Gastroenterologie und Rheumatologie